OPY
$83.50-0.94 (-1.11%)
Oppenheimer Holdings Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Oppenheimer Holdings Inc. operates as a middle-market investment bank and full-service broker-dealer in the Americas, Europe, the Middle East, and Asia. The company provides brokerage services covering corporate equity and debt securities, money mark...
Recent News
Why The Enpro (NPO) Story Is Shifting As Analysts Reassess Sales And Valuation
Enpro’s latest analyst update keeps the Fair Value at US$300, while a higher price target of US$285 is being used by some analysts as they recalibrate their views. The change is tied to research highlighting better Q4 outcomes, stronger Q4 2025 sales expectations around US$295M, and confidence in areas like AST cleaning solutions and Sealings. As you read on, you will see how these shifting targets and opinions can help you track the evolving Enpro story. Analyst Price Targets don't always...
Oppenheimer Initiates Ocugen (OCGN) With a Buy Rating
Ocugen, Inc. (NASDAQ:OCGN) is one of the High-Flying Penny Stocks to Buy. On March 11, Ocugen, Inc. (NASDAQ:OCGN) was initiated with an Outperform rating and a $10 price target at Oppenheimer. The firm noted that they find the company to be an upcoming leader in gene therapy for blinding ocular disorders. Oppenheimer highlighted the company’s […]
Morgan Stanley, Oppenheimer, and Goldman Sachs Raise Vertiv (VRT) Price Targets
Vertiv Holdings Co (NYSE:VRT) is one of the 10 Best AI Stocks to Buy for the Next 10 Years. On February 13, Morgan Stanley raised its price target on Vertiv Holdings Co (NYSE:VRT) from $200 to $285 and maintained its Overweight rating on the stock. The research firm said that it is confident in Vertiv […]
A Look At Soleno Therapeutics (SLNO) Valuation As Oppenheimer Updates Vykat XR Launch And 2026 Sales Outlook
Soleno Therapeutics (SLNO) is back in focus after an Oppenheimer report flagged expectations for a slower US launch of Vykat XR, yet suggested 2026 sales could still come in ahead of earlier forecasts. See our latest analysis for Soleno Therapeutics. Those expectations arrive after a choppy year for Soleno, with a 30 day share price return of 12.7% and a 90 day share price return of 29.8%. The very large 3 year total shareholder return highlights how quickly sentiment has shifted around Vykat...
The Ensign Group Touts 2026 Growth, Easing Labor and Busy Deal Pipeline at Oppenheimer Conference
The Ensign Group (NASDAQ:ENSG) told investors at Oppenheimer’s 36th Annual Healthcare MedTech & Services Conference that it exited the fourth quarter with what management described as broad-based operational momentum, improving labor trends, and an active acquisition environment—though pricing h